Savara Inc. (SVRA) is an orphan lung disease company based in Austin, Texas, that centers its attention on the unmet medical needs of rare pulmonary diseases. Its mission is to provide innovative therapeutic options for patients with serious or life-threatening rare respiratory diseases.
Since its inception, the publicly-traded company has shown notable devotion to researching and developing novel therapies that could potentially transform patients' lives. Savara Inc. specializes in the development and commercialization of novel therapies to address the unique health conditions and challenges that patients with rare lung diseases face.
The company is known for its leading investigational product, Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is presently being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease which occurs when protein and fat substances known as surfactants build up in the lungs and make breathing difficult.
Another major product in the company’s portfolio is AeroVanc, an inhaled dry powder form of vancomycin. AeroVanc is being investigated for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis.
As a pioneer in the field of rare lung diseases, Savara Inc. is committed to revolutionizing the treatment options available for patients across the globe. The company's work dramatically illustrates its commitment to improving patients' lives through its innovative therapeutic options.
Savara Inc.'s proactive approach to research and development, coupled with its patient-centric work ethic, place it firmly at the forefront of scientific progress in the field of rare lung diseases. Its clinical-stage pipelines offer significant potential for the future treatment of conditions that have previously been poorly addressed. Moreover, their collaboration with global communities of patients, caregivers, and health-care professionals furthers their commitment to lead to enhanced patient care and improved health outcomes worldwide.
In conclusion, Savara Inc. is a company with a strong purpose that extends beyond maximizing their bottom line. Their commitment to helping patients with rare lung conditions is commendable, and they are undoubtedly going to be a key player in the industry in the years to come, with the potential to make a real difference in people's lives.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Savara Inc.'s Chief Commercial Officer, Braden C. Parker, withheld 29,323 shares of common stock on September 24, 2026, to cover tax obligations from the vesting of restricted stock units. These shares were valued at $5.07 each. Following this transaction, Parker directly holds 75,677 shares of Savara common stock.
Savara Inc. (SVRA) is awaiting an FDA decision on its drug Molbreevi for autoimmune pulmonary alveolar proteinosis (aPAP), expected by November 22, 2026. If approved, Molbreevi would be the first specific treatment for aPAP, addressing a significant unmet medical need in this rare lung disease. The full article content is behind a paywall for RTT Biotech Investor and Intelligent Investor subscribers.
Savara Inc. reported a wider second-quarter loss of $40.2 million, or 16 cents per share, as it expanded its commercial operations in anticipation of a November 22 FDA decision on its rare-disease drug, MOLBREEVI. The company's general and administrative expenses increased significantly due to higher personnel costs and infrastructure building for the potential U.S. market launch. Savara ended the quarter with strong cash reserves and expects decisions on MOLBREEVI from European and U.K. regulators in late 2026 and early 2027, respectively.
Savara (SVRA) is attracting attention after reporting a net loss of US$40.23 million and filing a US$108.297 million shelf registration, despite its share price showing a 76.9% one-year return. The company's stock trades at a high price-to-book ratio of 9.9x, significantly above industry averages, suggesting investors are paying a premium based on expectations for its rare respiratory disease pipeline, specifically the Phase 3 molgramostim program. However, ongoing losses and the new shelf registration could temper investor sentiment.
Walleye Capital LLC has initiated a new position in Savara Inc. (NASDAQ:SVRA) by acquiring 248,720 shares valued at approximately $1.53 million during the second quarter. Despite mixed analyst sentiment, with a "Moderate Buy" consensus but recent downgrades, institutional investors collectively hold 87.93% of the company. Savara reported a quarterly loss exceeding expectations, and analysts project continued losses for the foreseeable future.
HC Wainwright has lowered its Q3 2026 earnings per share estimate for Savara to a loss of $0.16, down from $0.15, and projects full-year losses through 2028. This adjustment follows Savara's Q2 earnings report, where the company missed consensus estimates with a loss of $0.16 per share. Despite these revised estimates, analysts maintain a "Moderate Buy" rating for Savara with an average price target of $10.14, while institutional investors hold a significant 87.93% stake in the clinical-stage biotech firm.
HC Wainwright has revised its FY2029 EPS forecast for Savara Inc. (NASDAQ:SVRA) down to $0.09 from $0.11, while projecting FY2030 EPS at $0.37. This revision is still notably above the current full-year consensus estimate of a $0.57 loss per share. Savara recently reported a quarterly loss of $0.16 per share, missing analyst consensus, but its shares rose 2.3% to $5.70.